Debiopharm

✨Learning. Sharing. Connecting at #ESMO2025  Thrilled to have our team on the ground at the ESMO - European Society for Medical Oncology Congress, exploring the latest advances in cancer research. From DNA Damage Response (DDR) strategies to the evolving role of antibody-drug conjugates (ADCs), the discussions here are shaping the future of oncology. Our team is proud to contribute to these conversations and bring back valuable knowledge that will help optimize our preclinical and clinical programs. 📸 Here is a snapshot of our team, all committed to driving progress in precision oncology. Esteban Rodrigo Imedio, Werner Vogel, Angela Zubel, Catalin Tamas, Amina Benahmed, Heidi Nauwelaerts, Rita Paiva, Francesco Staehli, Julia Jauch-Lembach, Valerie Bernard-Martin, Blaise Calpe, Isabelle Delattre Petit, Stefano Panizza 🔬 Check out our drug development pipeline and follow us for more research updates https://lnkd.in/dkms_aY

📢A new milestone reached with Risklick in accelerating drug development with AI! At Debiopharm, we’re passionate about accelerating drug development through innovation, particularly by embracing cutting-edge AI-based technologies that can radically transform how we work. We’ve just achieved a key milestone with Risklick, one of our Innovation Fund portfolio companies. ✨   Their AI-powered Protocol AI™ is helping us to streamline oncology protocol development, saving time, boosting quality, and accelerating drug R&D. This is one way we’re integrating innovation to bring treatments to patients faster.  👇Read the press release for more info and follow us to stay updated on our efforts to reshape the future of cancer care. https://lnkd.in/eHaP7ytR  #Innovation #DrugDevelopment #AI #Oncology #CancerCare

Advancing cancer research with AI-powered innovation at #ESMO2025✨ We’re proud to see several of our Debiopharm Innovation Fund portfolio companies presenting their cutting-edge work at the ESMO - European Society for Medical Oncology Congress, driving progress in precision oncology through artificial intelligence and deep biological insights. 📈 Altis Labs is showcasing how IPRO outperforms conventional metrics, making it a powerful early endpoint for oncology trials. https://lnkd.in/eRKU-EaJ 🎯 Genialis will share an ePoster in collaboration with University Clinic Golnik, highlighting how AI and biological expertise come together to fulfill the promise of precision medicine. https://lnkd.in/e4zVAPSP 🧬 StratifAI is participating with a poster presentation on Polaris™, a platform designed to accelerate biomarker validation and bring precision oncology closer to everyday clinical practice. We’re inspired by their progress and proud to support their missions to make cancer treatment more personalized, accessible, and effective.   See you there! 👋 #CancerResearch #DrugDevelopment #AI #Oncology

Can Precision ADC Therapy Overcome Current Barriers in AML? 💡Acute Myeloid Leukemia (AML) remains one of the most aggressive and complex blood cancers, especially in patients who can't tolerate intensive chemotherapy. In this ADC Review | Journal of Antibody-drug Conjugates article by Dr. Marianna Muller and Dr. Lisa Ivanschitz, discover how our CD37-targeting ADC, Debio 1562M, could reshape the future of AML treatment.🔬 🎯Why target CD37 in AML?  ☑️Broad expression across AML subtypes ☑️Rapid internalization in leukemic cells ☑️Minimal presence in healthy tissues   Read the article and discover how targeted ADCs are bringing precision oncology to vulnerable AML patients.👇 https://lnkd.in/ekWfCsT8 #ADCs #AntibodyDrugConjugates #AcuteMyeloidLeukemia #PrecisionOncolog #PrecisionMedicine

Did you know that about 1 in 8 people globally live with a mental health condition? Yet, stigma and silence still prevent many from seeking help.   🧠Today, World Mental Health Day reminds us, mental well-being is a foundation for thriving individuals, teams, and organizations. ✨ At Debiopharm, we believe our employees well-being is fundamental to our shared success. We’re committed to fostering a workplace where employees feel safe, supported, and empowered to take action for their mental health, whether through confidential counseling, peer support, or our trained Mental Health First Aiders.   We know mental health is complex, today is a reminder to check in with ourselves and each other.

📢The finalists have been announced for the 2025 European Lifestars Awards - Celebrating Life Science Leaders! In pharma, we know that collaboration is essential to bring innovative solutions to patients faster. That’s why we partner. 🤝Last year we signed an exclusive worldwide rights agreement with ITM Isotope Technologies Munich SE for our CA IX-targeted peptide-based radiopharmaceutical programs for solid tumors – a deal representing a major step forward in our mission to advance precision oncology for patients around the globe.   We’re proud to be named as a finalist this year for the “Deal of the Year” category along with ITM Isotope Technologies Munich SE! Congrats to all finalists working hard to make a difference for patients! ✨ 👇 See all the finalists across categories here: https://lnkd.in/dNeDbkCx 📅Winners per category will be announced on November 17th in London! #Radiopharmaceutical #DrugDevelopment #PrecisionOncology #TargetedTherapy

After EANM 2025 in Barcelona, we’re bringing back the momentum sparked at this congress!✨ Our team found this year’s edition of the European Association of Nuclear Medicine (EANM) Annual Congress to be an incredible opportunity to connect with precision nuclear medicine experts, explore the latest innovations, and deepen our commitment to advancing radioligand therapy 💡We were particularly excited about updates on CAIX as an important emerging target for both diagnostic and therapeutic application.    👇 Learn more about our expertise in radioligand therapy here https://lnkd.in/eK7d4964 #EANM25 #NuclearMedicine #RadioligandTherapy #Oncology #PrecisionMedicine 📸 Simone Ragusa, Dr. Diana Pignalosa, Corinne Moulon, Emilie Da Costa Aude Colin

👏Congratulations to StratifAI for successfully closing their oversubscribed funding round. As a continued supporter, we're proud to back their vision for Polaris™ Breast, designed to predict breast cancer recurrence: when it comes to cancer recurrence, patients can’t afford to be patient, access to timely, accurate insights is critical.  As we enter 🎗️Pink October, this new funding will accelerate clinical validation, regulatory milestones, and partnerships with leading institutions, paving the way for guideline inclusion and real-world adoption. 👇Read their full press release to learn more https://lnkd.in/eJTg8Y7p #Startupfunding #AIBiomarkers #PrecisionOncology #BreastCancer

📢ADC Pipeline Expansion Alert! We're thrilled to announce a major step in advancing next-generation cancer therapies: We've licensed SunRock Biopharma, S.L 's bispecific anti-HER3/HER2 antibody (SRB21) to create Debio 2512!✨ This isn't just another molecule, it’s a powerful dual-targeting strategy to outsmart treatment resistance in aggressive HER-driven cancers. By combining SRB21 with our proprietary MultiLINK™ Linker Technology, we're applying our "Trifecta" approach to deliver a precisely-tailored ADC for higher efficacy and safer delivery.🎯   👇 Learn how this agreement could pave the way for breakthrough therapies against resistant tumors: https://lnkd.in/eqcjiSbS #ADCs #Innovation #Oncology #AntibodyDrugConjugates #LinkerTechnology

✨What an energetic evening exploring the future of Antibody-Drug Conjugates (ADCs) at the Swiss HLG Afterwork Networking Event hosted at our headquarters in Lausanne. With dynamic and insightful presentations around « Precision Meets Opportunity » we learned how ADC innovation is impacting the way we treat cancer.   Thank you to the Swiss HLG for organizing this smart opportunity for local ADC developers, to the outstanding speakers for sharing their practical experience and to all of the attendees for their participation in the networking apéro!👏 Bjoern Hock, Sophie Brachet, Ilona Kotala, Filippo Mulinacci Lambert Potin Peters Solange Laurence de Schoulepnikoff #ADCs #AntibodyDrugConjugates #ADCInnovation #Oncology 🔬 Explore our program pipeline here : https://lnkd.in/dkms_aY